Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 year

被引：0

作者：

Esser, Stefan ^{[1
]}

Inciarte, Alexy ^{[2
]}

Levy, Itzchak ^{[3
,4
]}

Monforte, Antonella D'Arminio ^{[5
]}

Lambert, John S. ^{[6
]}

Welzen, Berend van ^{[7
]}

Teruya, Katsuji ^{[8
]}

Boffito, Marta ^{[9
]}

Liu, Chun-Eng ^{[10
]}

Aydin, Ozlem A. ^{[11
]}

Thorpe, David ^{[12
]}

Heinzkill, Marion ^{[13
]}

Marongiu, Andrea ^{[12
]}

Cassidy, Tali ^{[12
]}

Haubrich, Richard ^{[14
]}

D'Amato, Lisa ^{[15
]}

Robineau, Olivier ^{[16
]}

机构：

[1] Univ Hosp Essen, Dept Venerol, Clin Dermatol, Essen, Germany

[2] Hosp Clin Barcelona, HIV Unit, Barcelona, Spain

[3] Tel Aviv Univ, Sheba Med Ctr, Infect Dis Unit, Tel Aviv, Israel

[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[5] Univ Milan, ASST Santi Paolo & Carlo, Milan, Italy

[6] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Dublin, Ireland

[7] Univ Med Ctr Utrecht, Utrecht, Netherlands

[8] NCGM AIDS Clin Ctr ACC, Natl Ctr Global Hlth & Med, Tokyo, Japan

[9] Chelsea & Westminster Hosp, London, England

[10] Changhua Christian Hosp, Dept Internal Med, Changhua, Taiwan

[11] Univ Hlth Sci, Basaksehir Cam & Sakura City Hosp, Istanbul, Turkiye

[12] Gilead Sci Ltd, Stockley Pk, England

[13] Gilead Sci GmbH, Martinsried, Germany

[14] Gilead Sci Inc, Foster City, CA USA

[15] Gilead Sci Srl, Milan, Italy

[16] Hop Guy Chatiliez, Tourcoing, France

来源：

FUTURE MICROBIOLOGY | 2024年 / 19卷 / 15期

关键词：

Antiretroviral therapy; HIV medicine; lay language summary; plain language summary; real-world data; treatment-experienced; treatment-naive;

D O I：

10.1080/17460913.2024.2391190

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

What is this summary about? This is a summary of an article about an ongoing study called the BICSTaR study. The BICSTaR study includes people with HIV (human immunodeficiency virus) who are taking a medicine called bictegravir/emtricitabine/tenofovir alafenamide (shortened to B/F/TAF). B/F/TAF is a single tablet that contains 3 different drugs for the treatment of HIV. The drugs work together to reduce the levels of HIV so that the virus can no longer be detected by a blood test. People taking part in the study are adults with HIV living in Europe, Canada, Israel, Japan, South Korea, Singapore and Taiwan. People take 1 tablet of B/F/TAF once a day. They are either taking B/F/TAF as their first treatment for HIV, or they have switched to B/F/TAF from another HIV treatment. Researchers looked at how well B/F/TAF worked and how safe it was in people who took B/F/TAF for a year. What are the key takeaways? Researchers found that B/F/TAF worked well in almost all people in the study by reducing levels of HIV in the blood. The virus could not be found in the blood of more than 9 out of 10 (94%) people who were taking B/F/TAF as their first HIV medicine and more than 9 out of 10 people (97%) who had taken another HIV medicine before starting B/F/TAF. This is known as having an 'undetectable viral load' and is a major goal for HIV treatment success. Researchers did not find any evidence of HIV developing resistance to B/F/TAF, which might stop B/F/TAF from working properly. Around 1 out of 10 people (13%) had side effects (any unwanted sign or symptom that people have when taking a medicine that researchers think might be caused by the medicine) that might have been caused by B/F/TAF. Most of these side effects were not classified as serious. Less than 1 out of 100 (0.1%) people had serious side effects that might have been caused by B/F/TAF. Only 6 out of 100 people stopped taking B/F/TAF due to side effects caused by B/F/TAF. As a result, more than 9 out of 10 people (95%) took B/F/TAF for at least 1 year. What were the main conclusions reported by the researchers? B/F/TAF worked well in people with HIV in this study. Most people (around 9 out of 10) did not have any side effects.

引用

页码：1273 / 1282

页数：10

共 49 条

[31] Metabolic Health Consequences of Switching to the Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir Plus Lamivudine Regimens in Virologically Suppressed People Living with HIV Aged > 40 Years: A Retrospective Real-World Study [J].

Shi, Jinchuan ;

Zhang, Wenhui ;

Han, Jie ;

Zhang, Zhongdong ;

Yan, Dingyan ;

Zheng, Rongrong ;

Li, Feng ;

Wang, Yi .

INFECTION AND DRUG RESISTANCE, 2025, 18 :2703-2716

[32] Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study [J].

Mata Marin, Jose Antonio ;

Velasco-Penagos, Juan Carlos ;

Mauss, Stefan ;

Rodriguez-Evaristo, Mara Soraya ;

Perez-Barragan, Edgar ;

Villa-Platas, Joaquin ;

Barragan-Huerta, Laura ;

Gaytan-Martinez, Jesus Enrique .

INTERNATIONAL JOURNAL OF STD & AIDS, 2024, 35 (01) :33-38

[33] Safety and efficacy of lamivudine/dolutegravir vs. bictegravir/ emtricitabine/tenofovir alafenamide in antiretroviral- naive adults with HIV-1 infection in Shanghai, China: a single- centre retrospective study [J].

Yang, Junyang ;

Wang, Lin ;

Zhang, Xiaoran ;

Liu, Li ;

Shen, Yinzhong ;

Qi, Tangkai ;

Wang, Zhenyan ;

Song, Wei ;

Tang, Yang ;

Xu, Shuibao ;

Sun, Jianjun ;

Chen, Youming ;

Shen, Yihong ;

Chen, Jun ;

Zhang, Renfang .

JOURNAL OF MEDICAL MICROBIOLOGY, 2025, 74 (01)

[34] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study [J].

Gan, Lin ;

Xie, Xiaoxin ;

Fu, Yanhua ;

Song, Yebing ;

Song, Chunli ;

Ren, Tingting ;

Long, Hai .

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (04) :211-217

[35] Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58) [J].

Imaz, Arkaitz ;

Tiraboschi, Juan M. ;

Niubo, Jordi ;

Martinez-Picado, Javier ;

Cottrell, Mackenzie L. ;

Domingo, Pere ;

Chivite, Ivan ;

Negredo, Eugenia ;

Schauer, Amanda ;

Van Horne, Brian ;

Morenilla, Sandra ;

Urrea, Victor ;

Silva-Klug, Ana ;

Scevola, Sofia ;

Garcia, Benito ;

Kashuba, Angela D. M. ;

Podzamczer, Daniel .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) :E1991-E1999

[36] Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens [J].

Chen, Guan-Jhou ;

Sun, Hsin-Yun ;

Chen, Ling-Ya ;

Hsieh, Szu-Min ;

Sheng, Wang-Hui ;

Liu, Wang-Da ;

Chuang, Yu-Chung ;

Huang, Yu-Shan ;

Lin, Kuan-Yin ;

Wu, Pei-Ying ;

Chang, Hsi-Yen ;

Luo, Yu-Zhen ;

Su, Yi-Ching ;

Liu, Wen-Chun ;

Chang, Sui-Fang ;

Chang, Sui-Yuan ;

Hung, Chien-Ching .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (03)

[37] Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age [J].

Maggiolo, Franco ;

Rizzardini, Giuliano ;

Molina, Jean-Michel ;

Pulido, Federico ;

De Wit, Stephane ;

Vandekerckhove, Linos ;

Berenguer, Juan ;

D'Antoni, Michelle L. ;

Blair, Christiana ;

Chuck, Susan K. ;

Piontkowsky, David ;

Martin, Hal ;

Haubrich, Richard ;

McNicholl, Ian R. ;

Gallant, Joel .

HIV MEDICINE, 2023, 24 (01) :27-36

[38] Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma [J].

不详 .

FUTURE ONCOLOGY, 2023, 19 (27) :1823-1840

[39] Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma [J].

Moreau, Philippe ;

van de Donk, Niels W. C. J. ;

Nahi, Hareth ;

Oriol, Albert ;

Nooka, Ajay K. ;

Martin, Thomas ;

Rosinol, Laura ;

Karlin, Lionel ;

Benboubker, Lotfi ;

Mateos, Maria-Victoria ;

Popat, Rakesh ;

Martinez-Lopez, Joaquin ;

Sidana, Surbhi ;

Delforge, Michel ;

Pei, Lixia ;

Trancucci, Danielle ;

Olyslager, Yunsi ;

Uhlar, Clarissa ;

Stephenson, Tara ;

Van Rampelbergh, Rian ;

Banerjee, Arnob ;

Kobos, Rachel ;

Usmani, Saad Z. .

FUTURE ONCOLOGY, 2023, 19 (12) :811-818

[40] Plain language summary of publication: new information for the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer [J].

Cadranel, Jacques .

FUTURE ONCOLOGY, 2022, 18 (18) :2192-2199

← 1 2 3 4 5 →